Equities research analysts expect that Kadmon Holdings Inc (NASDAQ:KDMN) will report sales of $4.35 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Kadmon Holdings’ earnings. The highest sales estimate is $7.70 million and the lowest is $1.00 million. Kadmon Holdings posted sales of $6.42 million in the same quarter last year, which would indicate a negative year over year growth rate of 32.2%. The firm is expected to announce its next earnings report on Wednesday, September 6th.

According to Zacks, analysts expect that Kadmon Holdings will report full-year sales of $4.35 million for the current year, with estimates ranging from $13.80 million to $24.59 million. For the next fiscal year, analysts expect that the business will report sales of $9.22 million per share, with estimates ranging from $4.93 million to $13.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Kadmon Holdings.

Kadmon Holdings (NASDAQ:KDMN) last issued its quarterly earnings results on Monday, May 15th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.13. The company had revenue of $5.60 million for the quarter, compared to analysts’ expectations of $4.25 million. The business’s quarterly revenue was down 42.3% on a year-over-year basis.

A number of analysts have commented on KDMN shares. Piper Jaffray Companies started coverage on shares of Kadmon Holdings in a report on Tuesday, March 14th. They set an “overweight” rating and a $7.00 target price for the company. WBB Securities raised shares of Kadmon Holdings from a “sell” rating to a “hold” rating and set a $3.25 target price for the company in a report on Thursday, March 16th. Citigroup Inc. reduced their target price on shares of Kadmon Holdings from $6.00 to $4.00 and set a “neutral” rating for the company in a report on Monday, March 27th. Zacks Investment Research raised shares of Kadmon Holdings from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Tuesday, March 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon Holdings in a report on Monday, June 26th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Kadmon Holdings presently has an average rating of “Buy” and a consensus price target of $12.21.

In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 767,363 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $3.50, for a total transaction of $2,685,770.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 1,456,208 shares of company stock valued at $5,157,324.

Several hedge funds have recently made changes to their positions in the company. Macquarie Group Ltd. purchased a new stake in shares of Kadmon Holdings during the fourth quarter worth about $2,696,000. Nationwide Fund Advisors purchased a new stake in shares of Kadmon Holdings during the first quarter worth about $192,000. Wells Fargo & Company MN boosted its stake in shares of Kadmon Holdings by 84.8% in the first quarter. Wells Fargo & Company MN now owns 51,291 shares of the company’s stock worth $186,000 after buying an additional 23,541 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Kadmon Holdings by 302.3% in the first quarter. Bank of New York Mellon Corp now owns 46,304 shares of the company’s stock worth $167,000 after buying an additional 34,794 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Kadmon Holdings by 11,654.8% in the first quarter. JPMorgan Chase & Co. now owns 228,866 shares of the company’s stock worth $829,000 after buying an additional 226,919 shares during the period.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/08/kadmon-holdings-inc-nasdaqkdmn-expected-to-announce-quarterly-sales-of-4-35-million.html.

Shares of Kadmon Holdings (KDMN) opened at 3.80 on Friday. The stock’s 50 day moving average is $2.80 and its 200 day moving average is $3.58. Kadmon Holdings has a 52 week low of $2.25 and a 52 week high of $10.48. The stock’s market cap is $197.01 million.

About Kadmon Holdings

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Get a free copy of the Zacks research report on Kadmon Holdings (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.